COPENHAGEN, Aug 20 (Reuters) - Denmark’s Novo Nordisk A/S said on Monday two Phase III studies of its hormone analogue Liraglutide had improved glucose control and lowered body weight in diabetes patients, sending its shares higher.
COPENHAGEN, Aug 20 (Reuters) - Denmark’s Novo Nordisk A/S said on Monday two Phase III studies of its hormone analogue Liraglutide had improved glucose control and lowered body weight in diabetes patients, sending its shares higher.
